This effect was even more pronounced when TPL was combined with cisplatin (DDP), which enhanced anti-tumor responses by decreasing markers of tumor vascularization (CD31) and M2 polarization (CD206), resulting in significant tumor growth inhibition and increased survival in vivo. The gene discussed is PECAM1; the disease is neoplasm.